UltraRapid Communication |
From the College of Pharmacy and the Dorothy M. Davis Heart and Lung Research Institute (C.A.C., R.S.B., S.P., J.A.B., D.R.V.W.), Ohio State University, Columbus, Ohio; Department of Cardiovascular Medicine (M.K.C., A.K., S.P., D.R.V.W.), Cleveland Clinic Foundation, Cleveland, Ohio; College of Veterinary Medicine (T.N., H.N., R.L.H.), Ohio State University, Columbus, Ohio; and Kaufmann Center for Heart Failure and Department of Cardiothoracic Surgery (P.M.M.), Cleveland Clinic Foundation, Cleveland, Ohio.
Correspondence to David R. Van Wagoner, PhD, Department of Cardiovascular Medicine, FF-10, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195-5069. E-mail vanwagd{at}ccf.org
Atrial fibrillation (AF), the most common chronic arrhythmia, increases the risk of stroke and is an independent predictor of mortality. Available pharmacological treatments have limited efficacy. Once initiated, AF tends to self-perpetuate, owing in part to electrophysiological remodeling in the atria; however, the fundamental mechanisms underlying this process are still unclear. We have recently demonstrated that chronic human AF is associated with increased atrial oxidative stress and peroxynitrite formation; we have now tested the hypothesis that these events participate in both pacing-induced atrial electrophysiological remodeling and in the occurrence of AF following cardiac surgery. In chronically instrumented dogs, we found that rapid (400 min-1) atrial pacing was associated with attenuation of the atrial effective refractory period (ERP). Treatment with ascorbate, an antioxidant and peroxynitrite decomposition catalyst, did not directly modify the ERP, but attenuated the pacing-induced atrial ERP shortening following 24 to 48 hours of pacing. Biochemical studies revealed that pacing was associated with decreased tissue ascorbate levels and increased protein nitration (a biomarker of peroxynitrite formation). Oral ascorbate supplementation attenuated both of these changes. To evaluate the clinical significance of these observations, supplemental ascorbate was given to 43 patients before, and for 5 days following, cardiac bypass graft surgery. Patients receiving ascorbate had a 16.3% incidence of postoperative AF, compared with 34.9% in control subjects. In combination, these studies suggest that oxidative stress underlies early atrial electrophysiological remodeling and offer novel insight into the etiology and potential treatment of an enigmatic and difficult to control arrhythmia. The full text of this article is available at http://www.circresaha.org.
Key Words: atrial fibrillation antioxidant ascorbate oxidative stress cardiac surgery
This article has been cited by other articles:
![]() |
K. B. Keller and L. Lemberg The Importance of Vitamin C in the Incidence of Atrial Fibrillation Am. J. Crit. Care., May 1, 2008; 17(3): 270 - 272. [Full Text] [PDF] |
||||
![]() |
A. Bukowska, L. Schild, G. Keilhoff, D. Hirte, M. Neumann, A. Gardemann, K. H. Neumann, F.-W. Rohl, C. Huth, A. Goette, et al. Mitochondrial Dysfunction and Redox Signaling in Atrial Tachyarrhythmia Experimental Biology and Medicine, May 1, 2008; 233(5): 558 - 574. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ozaydin, O. Peker, D. Erdogan, S. Kapan, Y. Turker, E. Varol, F. Ozguner, A. Dogan, and E. Ibrisim N-acetylcysteine for the prevention of postoperative atrial fibrillation: a prospective, randomized, placebo-controlled pilot study Eur. Heart J., March 1, 2008; 29(5): 625 - 631. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. M. Kim, H. Kattach, C. Ratnatunga, R. Pillai, K. M. Channon, and B. Casadei Association of atrial nicotinamide adenine dinucleotide phosphate oxidase activity with the development of atrial fibrillation after cardiac surgery. J. Am. Coll. Cardiol., January 1, 2008; 51(1): 68 - 74. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Carnes, P. M. L. Janssen, M. L. Ruehr, H. Nakayama, T. Nakayama, H. Haase, J. A. Bauer, M. K. Chung, I. M. Fearon, A. M. Gillinov, et al. Atrial Glutathione Content, Calcium Current, and Contractility J. Biol. Chem., September 21, 2007; 282(38): 28063 - 28073. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Guazzi, S. Belletti, E. Bianco, L. Lenatti, and M. D. Guazzi Endothelial dysfunction and exercise performance in lone atrial fibrillation or associated with hypertension or diabetes: different results with cardioversion Am J Physiol Heart Circ Physiol, August 1, 2006; 291(2): H921 - H928. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Shiroshita-Takeshita, B. J.J.M. Brundel, J. Lavoie, and S. Nattel Prednisone prevents atrial fibrillation promotion by atrial tachycardia remodeling in dogs Cardiovasc Res, March 1, 2006; 69(4): 865 - 875. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Korantzopoulos, T. M. Kolettis, and J. A. Goudevenos Effects of N-3 Fatty Acids on Postoperative Atrial Fibrillation Following Coronary Artery Bypass Surgery J. Am. Coll. Cardiol., January 17, 2006; 47(2): 467 - 468. [Full Text] [PDF] |
||||
![]() |
D. Amar, H. Zhang, P. M. Heerdt, B. Park, M. Fleisher, and H. T. Thaler Statin Use Is Associated With a Reduction in Atrial Fibrillation After Noncardiac Thoracic Surgery Independent of C-Reactive Protein Chest, November 1, 2005; 128(5): 3421 - 3427. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Korantzopoulos, T. M. Kolettis, K. Siogas, and J. A. Goudevenos The emerging role of inflammation in atrial fibrillation and the potential of anti-inflammatory interventions Eur. Heart J., October 2, 2005; 26(20): 2207 - 2208. [Full Text] [PDF] |
||||
![]() |
R. A. Garcia, K. L. Brown, R. S. Pavelec, K. V. Go, J. W. Covell, and F. J. Villarreal Abnormal cardiac wall motion and early matrix metalloproteinase activity Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1080 - H1087. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Shiroshita-Takeshita, G. Schram, J. Lavoie, and S. Nattel Effect of Simvastatin and Antioxidant Vitamins on Atrial Fibrillation Promotion by Atrial-Tachycardia Remodeling in Dogs Circulation, October 19, 2004; 110(16): 2313 - 2319. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. F Bosch and S. Nattel Cellular electrophysiology of atrial fibrillation Cardiovasc Res, May 1, 2002; 54(2): 259 - 269. [Full Text] [PDF] |
||||
![]() |
S. Nattel Therapeutic implications of atrial fibrillation mechanisms: can mechanistic insights be used to improve AF management? Cardiovasc Res, May 1, 2002; 54(2): 347 - 360. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |